PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Gabapentin - Pain (Neuropathic)

PAD Profile : Gabapentin - Pain (Neuropathic) Important

Keywords :
diabetic neuropathy, postherpetic neuralgia, PHN, neuropathic pain
Brand Names Include :
Neurontin
Important Information :
First line gabapentinoid.

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Capsules
  • Oral solution
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
CD
NICE
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
07 October 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Gabapentinoids are recommended as a teatment option at step 2 of the local neuropathic pain guidelines. 
Gabapentin is preferential to pregabalin due to its lower potential for misuse.
Pregabalin may be used if gabapentin is effective but not well tolerated OR if gabapentin is ineffective.

Gabapentinoids are Controlled Drugs and a maximum supply of 30 days should be prescribed at any time.

See guidelines and other resources relating to the use of gabapentinoids below

03 February 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Prescribers are reminded to undertake a proportionate risk benefit assessment prior to prescribing Pregabalin or Gabapentin for patients with a known or suspected propensity to misuse. See Advice to Prescribers document below

Associated BNF Codes

04. Central Nervous System
04.07.03. Neuropathic pain
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More